Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial - Concepedia

Concepedia

Publication | Open Access

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

DOI Full Paper Access

32

Citations

24

References

2021

Year

Mehmet Asım Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albigès, Lance C. Pagliaro, Éric Voog, Elaine T. Lam, Nikolay Kislov,

Clinical Cancer Research

Abstract

Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib.

References

	Year	Citations

Page 1